Formulation and Quality – Biomolecular
2019 PharmSci 360
Cancer immunotherapy takes advantage of the body’s own immune system to fight cancer. In antigen-specific immunotherapy, cancer-specific antigens are delivered to dendritic cells (DCs), which can initiate an immune response against the tumor by processing and presenting captured antigens to T cells. Despite great progress in recent years, there are still challenges that need to be addressed, such as insufficient induction of immune responses and off-target side effects of immunotherapeutics.
Here, instead of decorating preexisting particles with peptide or protein antigens of interest, we have developed a new class of protein nanoparticles that are entirely made of the model protein antigen (protein antigen nanoparticles, PANPs).
Overall, by tuning the elasticity of PANPs, we were able to alter the humoral and cellular responses in terms of their uptake by DCs, OT-1 CD8+ T cells proliferation and antibody production.